JBJanine Beezer

Janine Beezer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Janine Beezer has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Association Between Polypharmacy and Mortality in Patients with Heart Failure: Results from the PULSE Dataset

    by Janine Beezer, Andrew L. Clark, Adam Todd, Andrew Kingston, Andrew Husband

    Aims: Mortality remains high in heart failure despite advances in heart failure therapy. Heart failure patients are generally older, with multiple long-term conditions, and polypharmacy is common. This study explores the association between polypharmacy and mortality. Methods: This retrospective longitudinal observational cohort study collected medication data on admission and discharge from the first heart failure hospitalisation. Association with mortality was explored using Cox proportional hazard models and inverse probability weighting regression analysis. Results: A total of 660 patients were included, 367 (56%) male, mean age 76.1 (SD ±12.3) and almost 60% (338/660) had died at study end. Median follow-up time was 2.9 years (25th and 75th quartiles 1.6 and 4.5). It was rare to be discharged from hospital with no polypharmacy (5%, n = 31). Heart failure with preserved ejection fraction (HFpEF) was associated with a 32% (HR 1.32, CI 1.08–1.61, P = 0.007) higher mortality compared to HFrEF. In those with heart failure with reduced ejection fraction (HFrEF), univariable analysis showed hyperpolypharmacy was associated with twice the mortality compared to polypharmacy (HR 1.95, CI 1.36–2.82, P < 0.001). In multivariable analysis, the association between polypharmacy and mortality was lost. The average treatment effect for hyperpolypharmacy was associated with 26% (Coeff. −0.26, CI −0.43 to −0.09, P = 0.003) higher mortality than polypharmacy. The chance of survival to the end of follow-up was 80% (Coeff. 0.80, CI 0.64–0.95, P < 0.01) for those with polypharmacy, and 54% (Coeff. 0.54, CI 0.46–0.61, P < 0.01) for those with hyperpolypharmacy. In HFpEF, hyperpolypharmacy, univariable analysis was not associated with mortality (HR 0.93, CI 0.70–1.24, P = 0.63). Average treatment effect also showed that hyperpolypharmacy was not associated with mortality (Coeff. −0.03, CI −0.15 to 0.08, P = 0.55). The chance of survival to the end of follow-up was 67% (Coeff. 0.67, CI 0.58–0.77, P < 0.01) with polypharmacy and 64% (Coeff. 0.64, CI 0.57–0.71, P < 0.01) with hyperpolypharmacy. Conclusions: Age, sex, CCI, and CFS are strong mortality predictors for HF irrespective of HF subgroup. Rigorous confounding adjustment suggests polypharmacy is associated with mortality following hospitalisation for HFrEF but not HFpEF. Further studies are needed to address the complex interplay between polypharmacy, age, comorbidity, and frailty.


  • Polypharmacy on first admission to hospital for people with heart failure: baseline findings from the PULSE cohort

    by Janine Beezer, Andrew L Clark, Adam Todd, Andrew Kingston, John Casement, Lucy Pages, Andrew Husband

    Aims: To define and characterize polypharmacy in people with heart failure. Methods and results: The PULSE dataset is a bespoke single centre, retrospective, longitudinal, observational cohort database of patients hospitalized for heart failure, capturing data from the first heart failure admission through to death or end of data collection, including all subsequent admissions. First admission with heart failure was used to define baseline polypharmacy. There were 660 patients included in the dataset, 55.6% male, mean age 76.1 (±SD 12.3). Median number of medications on admission was 9 (25th–75th centile 7–12) and on discharge 10 (25th–75th centile 8–13). Polypharmacy prevalence was 87.3% on admission, increasing at discharge to 95.1% (P < 0.001). Mean medication complexity index score increased from 28.5 (±SD 14.9) at admission to 31.8 (±14.1) at discharge (P < 0.001). Number of medications on admission increased with increasing age (P < 0.001), higher Charlson Co-morbidity Index (P < 0.001), numerically more co-morbidities (P < 0.001), higher Clinical Frailty Scale (P < 0.001), longer length of stay (P = 0.03), worse New York Heart Association class of symptoms (P = 0.04), and a diagnosis of heart failure with preserved ejection fraction compared with heart failure with reduced ejection fraction (P = 0.002). Cardiovascular medications contributed 50% of medications. Prescribing of heart failure medications reduced with increased polypharmacy. Conclusion: Polypharmacy is common on first admission to hospital for people with heart failure. More medications at admission are associated with increasing age, co-morbidity, and frailty. People with polypharmacy are more likely to have a heart failure with preserved ejection fraction diagnosis, have worse symptoms and a longer hospital stay.


  • A retrospective cohort review of prescribing in hospitalised patients with heart failure using Beers criteria and STOPP recommendations

    by Janine Beezer, Lisa Roe, Andy Husband

    Background: With an ageing population and multimorbidity on the rise, polypharmacy is also increasing. Polypharmacy is common in patients with heart failure, possibly due to the application of evidence‐based therapy to improve prognosis and symptoms.Objectives: To identify potentially inappropriate medications according to Beers criteria and the STOPP screening tool; To assess if the recommendations generated from applying these tools could have potentially unintended harmful outcomes in the context of a heart failure diagnosis. Method: Medications for 30 patients, aged ≥75 years with an existing diagnosis of reduced ejection fraction (HFrEF) were extracted from the National Heart Failure Database. Patient medications were reviewed at the point of admission and recommendations documented and reviewed.Results: Patients were prescribed an average of 11 medicines. Beers criteria generated 22 recommendations, of which 27% (6) could have potential detrimental effects on patient outcomes. STOPP screening generated 54 recommendations of which 65% (35) were considered to have potentially unintended harmful consequences in patients with heart failure.Conclusions: Both guidelines for the review of potentially inappropriate medicines generated recommendations that could have potentially detrimental effects on heart failure management when considering patients with HFrEF.


  • Correction to: Polypharmacy definition and prevalence in heart failure: a systematic review

    by Janine Beezer, Manal Al Hatrushi, Andy Husband, Amanj Kurdi, Paul Forsyth


  • Top Cited Papers

    Polypharmacy definition and prevalence in heart failure: a systematic review

    by Janine Beezer, Manal Al Hatrushi, Andy Husband, Amanj Kurdi, Paul Forsyth

    Polypharmacy and heart failure are becoming increasingly common due to an ageing population and the rise of multimorbidity. Treating heart failure necessitates prescribing of multiple medications, in-line with national and international guidelines predisposing patients to polypharmacy. This review aims to identify how polypharmacy has been defined among heart failure patients in the literature, whether a standard definition in relation to heart failure could be identified and to describe the prevalence. The Healthcare Database Advanced Search (HDAS) was used to search EMBASE, MEDLINE, PubMed, Cinahl and PsychInfo from inception until March 2021. Articles were included of any design, in patients ≥ 18 years old, with a diagnosis of heart failure; that explicitly define and measure polypharmacy. Data were thereafter extracted and described using a narrative synthesis approach. A total of 7522 articles were identified with 22 meeting the inclusion criteria. No standard definition of polypharmacy was identified. The most common definition was that of “ ≥ 5 medications.” Polypharmacy prevalence was high in heart failure populations, ranging from 17.2 to 99%. Missing or heterogeneous methods for defining heart failure and poor patient cohort characterisation limited the impact of most studies. Polypharmacy, most commonly defined as ≥ 5 medications, is highly prevalent in the heart failure population. There is a need for an internationally agreed definition of polypharmacy, allowing accurate review of polypharmacy issues. Whether an arbitrary numerical cut-off is a suitable definition, rather than medication appropriateness, remains unclear. Further studies are necessary to understand the relationship between polypharmacy with specific types of heart failure and related comorbidities.